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Background
Human mesenchymal stem cells (hMSC) hold great pro-
mise as a tool in regenerative medicine and cell therapy.
Application of hMSC in cell therapy requires the ela-
boration of an appropriate serum-free (SF), xeno-free
(XF) culture system in order to minimize the health risk
of using xenogenic compounds, and to limit the immu-
nological reactions in-vivo. Besides the well-known dis-
advantages of serum, in comparison to a SF, XF culture
system, serum also exhibits poor performance in the
context of hMSC proliferation. In the present study, a
novel SF, XF culture system for hMSC suitable for ther-
apeutic applications was developed and evaluated. The
SF, XF culture system includes specially developed solu-
tions for attachment, dissociation, and freezing, as well
as a culture medium, MSC NutriStem® XF, that enables
long-term growth of multipotent hMSC. Development
of the SF, XF culture system was conducted on hMSC
from a variety of sources: bone marrow (BM), adipose
tissue (AT) and Wharton’s jelly (WJ).
Materials and methods
MSC NutriStem® XF culture medium was examined in
combination with MSC Attachment Solution (BI, 05-
752-1) and either Recombinant Trypsin Solution (BI,
03-078-1) or MSC Dissociation Solution (BI, 03-075-1).
The performance of MSC NutriStem® XF was evaluated
based on the following parameters: proliferation rate,
viability, morphology, stemness (estimated from CFU-F),
multilineage differentiation capability, and phenotypic
surface marker profile [1].
Cells
hMSC (passage 1-5) from a variety of sources: BM (Lonza,
Promocell), AT (Promocell, ATCC), and WJ (ATCC,
Prof. Mark Weiss - self isolation) were used in this study.
Culture System
hMSC were cultured in a SF, XF expansion medium
(MSC NutriStem® XF, BI) on pre-coated dishes (MSC
Attachment Solution, BI) or other media; commercial SF
media (Invitrogen; SCT, Promocell), in-house serum-
containing formulation (Prof. Mark Weiss). Cells were
seeded at 5000-6000 viable cells/cm2, and harvested using
either MSC Dissociation Solution (BI) or recombinant
Trypsin Dissociation Solution (BI).
Medium Performance Evaluation
Medium performance was evaluated by conducting
a comparison of proliferation rate, cell morphology,
multilinage differentiation potential into adipocytes,
osteocytes, and chondrocytes, self-renewal potential and
cell immunophenotype.
Cell Expansion
Cell proliferation was assessed by cell count using a trypan
blue exclusion assay at each time point.
Differentiation
hMSC expanded for 3-5 passages in MSC NutriStem®
XF were tested for maintenance of multilineage differen-
tiation potential (into adipocytes, osteocytes, and chon-
drocytes) using in-house differentiation formulations.
* Correspondence: mira@bioind.com
Biological Industries, Kibbutz Beit Haemek, Israel
Genser-Nir et al. BMC Proceedings 2013, 7(Suppl 6):P6
http://www.biomedcentral.com/1753-6561/7/S6/P6
© 2013 Genser-Nir et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Undifferentiated control cells were cultured in MSC
NutriStem® XF. Cells were fixed and stained with
Oil Red O, Alizarin Red/von Kossa, and Alcian blue/
Masson’s trichrome, respectively.
CFU-F Assay
hMSC were seeded at low densities (10, 50, and 100 cells/
cm2) in MSC NutriStem® XF, cultured for 14 days, and
stained with 0.5% crystal violet.
Flow Cytometry
WJ-derived hMSC were cultured for five passages in MSC
NutriStem® XF, followed by immunophenotype evaluation
by flow cytometry expression of CD73, CD90, CD105,
HLA-ABC (positive), HLA-DR, and CD45 (negative).
Results
An optimized SF, XF culture system for hMSC was devel-
oped, composed of growth medium, MSC NutriStem® XF,
and all the required auxiliary solutions for the attachment,
dissociation, and freezing of the cells. This SF, XF culture
system for hMSC, supported optimal expansion of hMSC
from a variety of sources, and exhibited superior prolifera-
tion compared with serum-containing media and com-
mercially available SF media. hMSC expanded in the SF,
XF culture system maintain their typical fibroblast-like cell
Figure 1 hMSC Features after culturing in MSC NutriStem® XF. Characterization of hMSC-WJ expanded for 5 passages in MSC NutriStem®
XF and in-house serum-containing formulation. Immunophenotype using FACS analysis (A), multilineage differentiation into adipocytes (Oil Red
O), osteocytes (von Kossa), and chondrocytes (Masson’s trichrome) (B), CFU-F assay (C). hMSC cultured in MSC NutriStem® XF maintains the
essential MSC characteristics; classical profile of MSC markers, multilineage differentiation, and self-renewal potential [1].
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morphology and phenotypic surface marker profile of
CD73, CD90, CD105, HLA-ABC (all positive), or CD34,
CD45, HLA-DR (all negative). hMSC differentiated effi-
ciently after expansion in the developed SF, XF culture
system into osteocytes, chondrocytes, and adipocytes. The
self-renewal potential was maintained as well, demon-
strated by a colony-forming unit fibroblast (CFU-F) assay
(Figure 1).
Conclusions
The use of serum is not an option from a regulatory point
of view. A SF, XF culture system for hMSC was developed
and enables long-term growth of multipotent hMSC suita-
ble for therapeutic applications. The performance of MSC
NutriStem® XF medium was proved to be superior to
serum-containing medium and commercially available SF
media. MSC NutriStem® XF medium supports long-term
culture of hMSC from a variety of sources, while retaining
the essential hMSC characteristics (fibroblast-like mor-
phology, surface markers phenotype, multilineage differen-
tiation, and self-renewal potential).The developed SF,
XF culture system (MSC NutriStem® XF medium, MSC
Attachment Solution, either MSC Dissociation Solution
or Recombinant Trypsin solution, and MSC Freezing
Solution) supports the expansion of hMSC suitable for
clinical applications.
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